^
BIOMARKER:

Chr del(11)(q22.3)

News
Twitter
Trials
Chr del(11)(q22.3)
CLL
ibrutinib
Sensitive: B - Late Trials
Chr del(11)(q22.3)
CLL
rituximab + ibrutinib
Sensitive: B - Late Trials
Chr del(11)(q22.3)
CLL
acalabrutinib
Sensitive: B - Late Trials
Chr del(11)(q22.3)
CLL
alemtuzumab
Sensitive: C3 – Early Trials
Chr del(11)(q22.3)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: C3 – Early Trials